Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) will present an overview of its lead program, STAR-0215, at the Jefferies Healthcare Conference on June 10 at 10:30 AM ET in New York. STAR-0215 is a monoclonal antibody aimed at treating hereditary angioedema, a rare immunological condition. The presentation will be led by CEO Jill C. Milne, Ph.D., and a webcast link is provided for access. An archived replay will be available on the company’s investor website for 30 days post-event.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming Jefferies Healthcare Conference on Friday, June 10^th at 10:30am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff240/atxs/1869600. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005022/en/

Astria Contacts:

Investor relations:

Andrea Matthews

investors@astriatx.com

Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics

FAQ

What is the date and time of Astria Therapeutics' presentation at the Jefferies Healthcare Conference?

Astria Therapeutics will present on June 10 at 10:30 AM ET.

Where can I watch the webcast of the Astria Therapeutics presentation?

The webcast can be accessed at https://wsw.com/webcast/jeff240/atxs/1869600.

What is STAR-0215 developed by Astria Therapeutics?

STAR-0215 is a monoclonal antibody targeting hereditary angioedema, currently in preclinical development.

Who is presenting for Astria Therapeutics at the conference?

Jill C. Milne, Ph.D., the CEO of Astria Therapeutics, will present.

How long will the archived presentation be available?

The archived presentation will be available for 30 days on the Astria Therapeutics investor section.